Kyunghee Burkitt

Summary

Affiliation: University of Michigan
Country: USA

Publications

  1. ncbi Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
    Kyunghee Burkitt
    Department of Radiation Oncology, Division of Radiation Cancer Biology, University of Michigan Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Mol Cancer 7:24. 2008
  2. ncbi Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines
    Kyunghee Burkitt
    Department of Radiation Oncology, University of Michigan Medical School, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Cancer Lett 253:131-7. 2007
  3. ncbi Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
    Kyunghee Burkitt
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA
    Mol Cancer Ther 8:1148-56. 2009
  4. ncbi Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
    Duyen T Dang
    Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Cancer Res 68:1872-80. 2008

Collaborators

Detail Information

Publications4

  1. ncbi Phenylbutyrate interferes with the Fanconi anemia and BRCA pathway and sensitizes head and neck cancer cells to cisplatin
    Kyunghee Burkitt
    Department of Radiation Oncology, Division of Radiation Cancer Biology, University of Michigan Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    Mol Cancer 7:24. 2008
    ..In this study we explored whether phenylbutyrate may sensitize head and neck cancer cells by interfering with the Fanconi anemia pathway...
  2. ncbi Compromised Fanconi anemia response due to BRCA1 deficiency in cisplatin-sensitive head and neck cancer cell lines
    Kyunghee Burkitt
    Department of Radiation Oncology, University of Michigan Medical School, University of Michigan, Ann Arbor, MI 48109 2200, USA
    Cancer Lett 253:131-7. 2007
    ..These results suggest a possible role for BRCA1 in modulating cisplatin sensitivity in head and neck cancer cells...
  3. ncbi Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment
    Kyunghee Burkitt
    Division of Hematology Oncology, Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, University of Michigan, Ann Arbor, Michigan 48109, USA
    Mol Cancer Ther 8:1148-56. 2009
    ..Second, disruption of HIF-1α, HIF-2α, or both HIF-1α and HIF-2α genes directly inhibited tumor cell proliferation. These preclinical findings have clinical implications and suggest novel clinical trials...
  4. ncbi Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition
    Duyen T Dang
    Department of Internal Medicine, The University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Cancer Res 68:1872-80. 2008
    ..The data further show that DPP4 is a novel marker of HIF-1 induction. Altogether, these preclinical findings suggest novel clinical trials for predicting and monitoring tumor vessel responses to antiangiogenic therapy...